Janiczek Wealth Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Janiczek Wealth Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-405	Closed	-$1.73K	–	1030
2023 Q1	$1.73K	Hold	405	–	–	﹤0.01%	782
2022 Q4	$2.35K	Hold	405	–	–	﹤0.01%	753
2022 Q3	$2K	Hold	405	–	–	﹤0.01%	794
2022 Q2	$3K	Buy	405 +215	+113%	+$1.1K	﹤0.01%	754
2022 Q1	$1K	Hold	190	–	–	﹤0.01%	928
2021 Q4	$0	Buy	+190	New	+$465	﹤0.01%	1126

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Janiczek Wealth Management's CTIC Position: Q2 2023 in Review

Janiczek Wealth Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 405 shares — an estimated $1.73K sold.

Janiczek Wealth Management first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $3K in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Janiczek Wealth Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Janiczek Wealth Management sold 405 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $1.73K.
Janiczek Wealth Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
Janiczek Wealth Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $3K in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Janiczek Wealth Management's 13F filing for Q2 2023, filed 11 Jul 2023.